Targeting Ribosome Biogenesis in Cancer: Lessons Learned and Way Forward

Area of Science:

• Molecular Biology
• Cancer Research
• Drug Discovery

Background:

• Cancer cells exhibit rapid growth and proliferation, necessitating increased metabolic and biosynthetic activities.
• Ribosome biogenesis (RiBi) is a critical, energy-intensive process supporting cancer cell growth.
• Existing chemotherapeutics targeting RiBi have limitations in specificity and pharmacological properties.

Purpose of the Study:

• To provide a comprehensive overview of compounds targeting ribosome biogenesis (RiBi) in cancer.
• To discuss mechanisms of action, screening strategies, and drug repurposing for RiBi inhibitors.
• To explore emerging discovery paths and potential biomarkers for RiBi-targeted cancer therapy.

Main Methods:

• Literature review of existing and novel compounds targeting RiBi.
• Analysis of mechanisms of action for RiBi inhibitors.
• Discussion of screening methodologies and drug repurposing approaches.

Main Results:

• Several classes of compounds effectively inhibit RiBi by interfering with rRNA transcription or nucleotide supply.
• Established inhibitors like actinomycin D and oxaliplatin demonstrate RiBi disruption.
• Emerging research tools and novel inhibitors are advancing the understanding of RiBi pathways.

Conclusions:

• Targeting ribosome biogenesis (RiBi) presents a promising strategy for cancer therapy.
• Improved compound specificity and pharmacological profiles are key areas for future development.
• Biomarkers are needed to predict therapeutic outcomes for RiBi-targeted treatments across diverse cancer subtypes.